Trials / Completed
CompletedNCT02450812
Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany
URANIS -Data Collection in Urological Centers During Treatment With Ra-223 Dichloride (Xofigo) Within the Framework of a Non-interventional Study Assessing Overall Survival (OS) and Effectiveness Predictors of Ra-223 Dichloride Treated mCRPC Patients in a Real Life Setting in Germany.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 86 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational prospective single arm cohort study is designed to assess overall survival, symptomatic skeletal event free survival and quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium- 223 under real life conditions. In addition, time to next tumor treatment (TTNT), mobility, quality of life and selfcare, independence in activities of daily living and safety will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Radium-223-dichloride (Xofigo, BAY88-8223) | according to Summary of Product Characteristics |
Timeline
- Start date
- 2015-05-28
- Primary completion
- 2020-06-30
- Completion
- 2020-09-17
- First posted
- 2015-05-21
- Last updated
- 2021-11-02
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02450812. Inclusion in this directory is not an endorsement.